NCT07085611 Neutralizing Power of Serum Antibodies - 2
| NCT ID | NCT07085611 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Régional d'Orléans |
| Condition | COVID-19 |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-08-22 |
| Primary Completion | 2030-08-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-08-22 with a primary completion date of 2030-08-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) * Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies * Patients have provided written informed consent Exclusion Criteria: * Persons under guardianship or curatorship * Persons under legal protection, * Persons persons deprived of liberty * Persons not affiliated to a social security scheme * Pregnant or breastfeeding women
Contact & Investigator
Thierry PRAZUCK, Dr
PRINCIPAL INVESTIGATOR
CHU Orléans
Frequently Asked Questions
Who can join the NCT07085611 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07085611 currently recruiting?
Yes, NCT07085611 is actively recruiting participants. Contact the research team at thierry.prazuck@chu-orleans.fr for enrollment information.
Where is the NCT07085611 trial being conducted?
This trial is being conducted at Orléans, France.
Who is sponsoring the NCT07085611 clinical trial?
NCT07085611 is sponsored by Centre Hospitalier Régional d'Orléans. The principal investigator is Thierry PRAZUCK, Dr at CHU Orléans. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.